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Several genetic studies have demonstrated an association between mutations in glucocerebrosidase
(GBA), originally implicated in Gaucher’s disease, and an increased risk of Parkinson’s disease (PD). We
have investigated the possible involvement of genetic GBA variations in PD in the Swedish population.
Three GBA variants, E326K, N370S, and L444P were screened in the largest Swedish Parkinson cohort
reported to date; 1625 cases and 2025 control individuals. We found a signiﬁcant association with high
effect size of the rare variant L444P with PD (odds ratio 8.17; 95% conﬁdence interval: 2.51e26.23; p-
value ¼ 0.0020) and a signiﬁcant association of the common variant E326K (odds ratio 1.60; 95% con-
ﬁdence interval: 1.16e2.22; p-value ¼ 0.026). The rare variant N370S showed a trend for association.
Most L444P carriers (68%) were found to reside in northern Sweden, which is consistent with a higher
prevalence of Gaucher’s disease in this part of the country. Our ﬁndings support the role of GBA mu-
tations as risk factors for PD and point to lysosomal dysfunction as a mechanism contributing to PD
etiology.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction body dementia with Alzheimer-like neuropathologic changes, butThe human glucocerebrosidase gene (GBA) is located on chro-
mosome 1q21 and encodes a lysosomal protein, which cleaves the
beta-glycosidic bond of glucosylceramide, an intermediate formed
during glycolipid metabolism (Brady et al., 1965). Mutations in GBA,
originally implicated in Gaucher’s disease (GD), have been identi-
ﬁed both in familial and sporadic Parkinson’s disease (PD; Balicki
and Beutler, 1995; Lwin et al., 2004). These mutations also seem
to inﬂuence the risk of developing Lewy body dementia and Lewycience, Karolinska Institutet,
46-8-524 87051.
elin).
r Inc. This is an open access articledo not associatewith Alzheimer’s disease (Clark et al., 2009; Tsuang
et al., 2012). Genetic alterations of GBA, a-synuclein (SNCA), and
leucine-rich repeat kinase 2 (LRRK2) together constitute the most
common known genetic risk-factors for sporadic PD today (Ran and
Belin, 2014).
Genetic variations in GBA are known to alter glucocerebrosidase
(GCase) activity and decreased GCase activity, and protein levels
have repeatedly been reported in brain tissue from PD patients with
GBA mutations (Gegg et al., 2012; Lwin et al., 2004; Mazzulli et al.,
2011). Interestingly, PD patients without GBA mutations were
recently reported to have lower GCase activity as compared with
healthy controls, suggesting GBA is involved in the pathologic
mechanisms of PD even in the absence of known GBA geneunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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et al., 2014). The most frequent mutations in GBA reported to be
associated with increased risk of PD are L444P and N370S
(Sidransky et al., 2009). The associations of these 2 mutations with
PD have been observed in populations with diverse genetic back-
grounds and represent over 50% of the pathogenic GBA mutations
found in patients globally (Sidransky et al., 2009). These ﬁndings
were veriﬁed in a large European study comprising almost 1400
sporadic and familial PD patients, where L444P or N370S were
found in 70% of the GBA mutation carriers (Lesage et al., 2011).
Many other GBAmutations have been reported to inﬂuence the risk
of developing PD, and the frequency of each variant differs globally
according to genetic background (Gan-Or et al., 2015; Sidransky
et al., 2009). In particular, GBA mutations are more common in
subjects with Ashkenazi Jewish ancestry (Aharon-Peretz et al.,
2004; Gan-Or et al., 2008; Sidransky et al., 2009).
Not only rare mutations but also single nucleotide poly-
morphisms (SNPs) such as E326K have been suggested to affect the
risk of developing PD (Clark et al., 2007; Lwin et al., 2004). E326K
has been reported to associate with PD in European populations,
although there are conﬂicting results (Lesage et al., 2011; Sidransky
et al., 2009). The associationwith E326K is particularly strong in PD
patients with early disease onset and suggested to result in an
aggravated phenotype with cognitive decline (Duran et al., 2013;
Mata et al., 2015). GCase activity measured in post-mortem brains
of PD patients heterozygous for E326K ranged between 90% and
100% of the activity in wild-type carriers (Lwin et al., 2004), but in
combination with other GBA mutations, for example L444P, the
E326K mutation leads to further deterioration of enzymatic activity
(Chabas et al., 2005; Montfort et al., 2004).
GBA mutations have not frequently reached signiﬁcance in
genome-wide association studies (GWAS), probably because of the
low minor allele frequencies of PD associated GBA mutations and
the methodological difﬁculties in avoiding contaminating signals
from the pseudogene GBAP1 (glucosidase, beta, acid pseudogene 1).
Other factors that might inﬂuence the outcome of a GWAS are
which genetic markers are included and how these are linked to
disease associated variants. Nevertheless, 2 GWAS studies pub-
lished in 2011 and 2012 reported association between PD and
N370S, and one of them further supports the E326K association (Do
et al., 2011; Pankratz et al., 2012). These data have also been
conﬁrmed in largemeta-analyses (Lill et al., 2012; Nalls et al., 2014).
Parkinson patients carrying heterozygous GBA mutations are
characterized by relatively early disease onset, but are otherwise
clinically similar to patients with sporadic PD and respondwell to L-
DOPA (Clark et al., 2007). However, patients with GBA mutations
have been reported to be more likely to suffer from nonmotor
symptoms, in particular cognitive impairment and dementia
(Alcalayet al., 2012;Mata et al., 2015; Seto-Salvia et al., 2012). Togain
insight into the role of GBA in the etiology of PD in the relativelyTable 1
Demographic data for the Parkinson patients and control populations
Variable Gothenburg Linköping
PD CTRL PD CTRL
Individuals, n 171 190 195 366
Mean age at enrollment, y 68.2 69.1 71.4 70.1
Mean age at diagnosis, y 59.0 NA 63.6 NA
Females, n (%) 74 (43.3) 120 (63.2) 74 (38.0) 185 (50.5)
Heredity, n (%) 41 (24.0) NA 42 (21.5) NA
Heredity was deﬁned as having one or more ﬁrst, second, or third degree relatives with
Key: CTRL, control subjects; NA, data not applicable; PD, Parkinson’s disease.
a Calculation based on 355 individuals for whom this information was available.
b Calculation based on the 416 individuals for whom this information was available, thomogenous Swedish population, we investigated the presence of 3
most reported nonsynonymous GBA variants in PD, N370S, L444P,
and E326K, among Swedish Parkinson patients and controls. In the
light of the particularly elevated prevalence of GBA mutations in
individuals with Ashkenazi Jewish descent, the Swedish population,
which has not previously been screened for GBA mutations, is
especially interesting to study as there is a known occurrence of GD
type III (Norrbottnian type) in northern Sweden (Dahl et al., 1990).
2. Materials and methods
2.1. Human DNA and tissue
A total of 1625 Swedish PD patients were recruited from the
neurology clinics at Karolinska University Hospital, Stockholm,
Sahlgrenska University Hospital, Gothenburg, Skåne University
Hospital, Lund, Umeå University Hospital, Umeå and Linköping
University Hospital, Linköping. Patient material was obtained after
informed consent and approval of the local ethics committees in
Stockholm, Gothenburg, Lund, Umeå, and Linköping, respectively
(http://www.epn.se). Information on cognitive decline was only
available for patients from Lund and was reported for 33 of the 122
patients (27.9%) which were also included in the genetic screening.
The PD patients were diagnosed according to the United Kingdom
Parkinson’s Disease Society Brain Bank criteria for idiopathic PD,
including patients who declared having one or more ﬁrst, second,
or third degree relatives with PD to get a large material (Gibb and
Lees, 1988). The 2025 Swedish control subjects were recruited
from the corresponding catchment areas as the patient material
and consisted of spouses of PD patients, individuals visiting the
neurology clinic, blood donors, and subjects recruited from an
ongoing longitudinal study, SNAC-K (The Swedish National Study
on Aging and Care in Kungsholmen, http://www.snac-k.se/), see
Table 1 for further site speciﬁc demographic information. Screen-
ings of known PD mutations in LRRK2 and SNCA have been per-
formed previously on a subset of the joint case-control material
(Carmine Belin et al., 2006; Puschmann, 2011; Westerlund et al.,
2008). All subjects were unrelated and a majority of Caucasian
origin (>95%). DNA was extracted from whole blood according to
standard protocols.
2.2. Genotyping
2.2.1. Pyrosequencing
The 3 genetic GBA variants were genotyped by pyrosequencing
(Ronaghi et al., 1998), except for a fraction of samples which were
genotyped for N370S with TaqMan (see paragraph 2.2.2 on TaqMan
SNP genotyping for details). Primer sequences are available on
request (Thermo Scientiﬁc, MA, USA). Primers were designed using
free online software (Primer 3 v4.0.0 andmFold v3.6; Koressaar andLund Stockholm Umeå
PD CTRL PD CTRL PD CTRL
122 43 528 1271 609 155
69.9 67.9 67.4 71.6b 68.9 64.1
61.9 NA 58.8a NA 62.9 NA
48 (37.7) 27 (62.8) 193 (36.55) 631 (49.9) 225 (36.9) 77 (49.6)
68 (54.8) NA 125 (36.8)a NA 121 (19.9) NA
PD.
he remaining 855 controls were blood donors.
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primers in each primer-pair was biotinylated at the 5’-end to allow
subsequent immobilization to streptavidin-coated beads. All
primers were designed to bind speciﬁcally to GBA by targeting parts
of the sequence that varied between GBA and the pseudogene
GBAP1. A polymerase chain reaction (PCR) reaction was run for 45
cycles at 95 C for 20 seconds, annealing for 20 seconds at different
temperatures: 57 C for N370S (rs76763715), and 60 C for L444P
(rs421016) and E326K (rs2230288). After PCR, the biotinylated
PCR product was immobilized to streptavidin-coated beads
(GE Healthcare, Buckinghamshire, United Kingdom), mixed for
10 minutes at room temperature and captured onto ﬁlter probes
(PyroMark Vacuum Prep Tool, Qiagen, Venlo, the Netherlands). The
ﬁlter probes were ﬂushed with 70% ethanol,1M NaOH denaturation
solution, and washing buffer and the single-stranded template was
annealed to the sequencing primer at 80 C for N370S, L444P, and
90 C for E326 K for 2e3 minutes. All solutions used in sample
preparation were made according to manufacturer’s instructions
(QIAGEN). Samples were analyzed on an automated pyrosequencer
(PSQ 96 System with SNP Software and PyroMark GOLD Reagent
Kits; QIAGEN).
2.2.2. TaqMan SNP genotyping
Two hundred forty-nine samples from Karolinska University
Hospital,165 samples fromSkåneUniversityHospital, Lund, and854
samples from Umeå University were genotyped for N370S using
TaqMan SNP genotyping (ABI 3730 DNA Analyzer instrument;
Applied Biosystems, Carlsbad, CA, USA).We used a custom-designed
assay (forward primer: 50 GTG ACC CTT ACC TAC ACT CTC T, reverse
primer: 50 GGT TCA GGG CAA GGT TCC), the reverse primer being
speciﬁc for the GBA gene, thus excluding the pseudogene GBAP1.
Allelic discriminationwas runwith 2 50 ﬂuorescence-labeled allele-
speciﬁc probes: C_2286559_30 and C_2268560_20, genotyping
master mix (TaqMan, Applied Biosystems), and 20 ng of genomic
DNA. We used the default PCR fast cycling conditions, 10 minutes at
95 C, 15 seconds at 92 C, and 1 minute at 60 C, for 40 cycles.
Analysiswas performedwith software suppliedwith the instrument
(QuantStudio 6 and 7, Flex Real-Time PCR System Software v1.0).
Mutation carriers detected with TaqMan were resequenced by
pyrosequencing to conﬁrm results.
2.3. Statistical analysis
We achieved a call rate of 95.3% for E326K, 95.8% for N370S, and
97.4% for L444P. Genotypic and allelic associations were evaluated
separately for southern and northern Sweden because of uneven
geographical distribution of mutation carriers. Analysis was per-
formed under a dominant model, using appropriate software
(Prism 5.03; GraphPad Softwares Inc, La Jolla, CA, USA) with chi-
square (c2) and Fisher’s exact test, signiﬁcance level 5%, 2-sidedTable 2
Genotype frequencies and test statistics of E326K, N370S, and L444P
SNP Genotype Southern Sweden
CTRL, n (%) PD, n (%) c2 (df) OR (CI)
E326K CC 1731 (96.65) 898 (94.83) 4.93 (1) 1.57 (1.07e2.32)
CT/TT 59 (3.35) 48 (5.17)
N370S TT 1768 (99.89) 971 (99.28) 5.29 (1) 6.73 (1.32e30.75)
TC/CC 2 (0.11) 7 (0.72)
L444P AA 1812 (99.89) 971 (98.98) 10.27 (1) 9.33 (2.04e42.69)
AG/GG 2 (0.11) 10 (1.02)
Southern Sweden comprises the geographic areas of Stockholm, Gothenburg, Linköping, a
Key: CI, 95% conﬁdence interval; CTRL, control individuals; df, degrees of freedom; NA, no
testing; PD, Parkinson’s disease; SNP, single nucleotide polymorphism.p-values. Results were compared between southern and northern
Sweden by means of a meta-analysis based on the odds ratio (ORs)
obtained from the dominant genotype analysis. Meta-analysis
included Cochran’s Q statistics and calculation of the heterogene-
ity index I2 as a measure of consistency between studies and was
performed in PLINK v1.07 (Purcell et al., 2007). The meta-analysis
was run under a random-effects model. Bonferroni correction for
multiple testing was used in both the association analysis and the
meta-analysis. We used a c2 Hardy-Weinberg equilibrium (HWE)
test to calculate HWE for each variation in the control population
(Rodriguez et al., 2009). To compare demographic characteristics
between groups, unpaired Student’s t test was used; 2-tailed p-
values (Prism 5.03).
3. Results
3.1. Association analysis
Our study included 3 genetic variations in GBA, 2 raremutations:
N370S and L444P, and the more common SNP, E326K. Parkinson
patients and healthy control individuals from 5 different geographic
locations in Sweden were analyzed. We found that the 2 rare var-
iants occurredmore often in PD patients than in healthy individuals
(Table 2). Furthermore, E326K was overrepresented in PD patients,
with a minor allele frequency of 3.05%, versus 1.75% in controls.
None of the identiﬁed GBAmutation carriers have been reported to
carry SNCA and/or LRRK2 mutations to date (Carmine Belin et al.,
2006; Puschmann, 2011; Westerlund et al., 2008). When
comparing site-speciﬁc genotype data, we discovered that L444P
was more common in the cohort collected in Umeå in northern
Sweden where 4.11% of the PD patients were heterozygous for
L444P as compared with 0.79% of the patients in Stockholm, 2.47%
in Gothenburg, and 1.72% in Lund. In total, 26 of the identiﬁed
L444P carriers (68%) were from the northernmost Swedish prov-
inces (Norrbotten and Västerbotten). Considering the skewed
geographical distribution of L444P carriers in favor of Norrbotten
and Västerbotten, and the elevated incidence of GD type III in the
north provinces, we decided to analyze genotype data from
southern Sweden (Gothenburg, Linköping, Stockholm, and Lund)
and northern Sweden (Umeå) separately (Dahl et al., 1990). In
performing a separate analysis for these 2 groups, we further avoid
any bias that might be introduced in our analysis by the genetic
population stratiﬁcation that occurs in the Swedish population
between northern and southern counties (Humphreys et al., 2011).
The E326K variationwas in HWE in controls from southern Sweden
but not in controls from northern Sweden. Because of the lack of
homozygousmutation carriers, we could not performHWE analysis
for N370S and L444P.
Statistical analysis showed that L444P was signiﬁcantly associ-
ated with PD in southern Sweden (Table 2). L444P had an OR ofNorthern Sweden
pc-value CTRL, n (%) PD, n (%) c2 (df) OR (CI) pc-value
0.081 141 (95.92) 552 (92.93) NA 1.79 (0.75e4.29) 0.78
6 (4.08) 42 (7.07)
0.065 152 (100) 595 (99.50) NA 1.79 (0.09e34.92) 1
0 3 (0.50)
0.0039 151 (99.34) 583 (95.89) NA 6.49 (0.87e48.28) 0.13
1 (0.66) 25 (4.11)
nd Lund; Northern Sweden comprises samples collected at Umeå University Hospital.
t applicable; OR, odds ratio; pc-value, p-value after Bonferroni correction for multiple
Table 3
Meta-analysis of the southern and northern Swedish populations
SNP pc-value Pooled OR 95% CI Q I2
E326K 0.026 1.60 1.16e2.22 0.99 0.00
N370S 0.068 5.04 1.10e23.04 0.41 0.00
L444P 0.0020 8.17 2.51e26.63 0.77 0.00
Key: 95% CI, 95% conﬁdence interval; I2, I2 heterogeneity index; OR, random-effects
meta-analysis odds ratio; pc-value, random-effects meta-analysis p-value with
Bonferroni correction for multiple testing; Q, p-value for Cochran’s Q statistic; SNP,
single nucleotide polymorphism.
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value after Bonferroni correction for multiple testing (pc) of 0.0039.
Genotype analysis of N370S and E326K showed a trend for associ-
ation with PD in southern Sweden (Table 2). N370S had an OR of
6.73; 95% CI, 1.32e30.75, and a crude p-value of 0.022, but the as-
sociation did not remain signiﬁcant after correction for multiple
testing, pc ¼ 0.065. The corresponding values for E326K were OR¼
1.57, 95% CI: 1.07e2.32, p-value¼ 0.027, which also lost signiﬁcance
after Bonferroni correction. Allele analysis did not add substantial
information (data not shown) with the exception of conﬁrming the
association between the minor allele (C) of N370S and an increased
risk of developing PD (OR ¼7.27; 95% CI, 1.54e34.26; pc ¼ 0.028).
In the northern Swedish case-control material, all 3 GBA variants
were overrepresented, and in particular L444P, which was present
in 4.11% of the PD patients, as compared with 1.02% of the PD
patients in southern Sweden. Statistical testing in this patient group
was inconclusive, probably because of the low number of controls
(Table 2). However, L444P showed a trend for association with an
OR of 6.49 and a p-value of 0.042, but the CI overlaps 0 (95% CI,
0.87e48.28), and the p-value did not hold for Bonferroni correction
(pc ¼ 0.13).
The distribution of mutation carriers was equal between sexes;
24 female carriers and 26 male carriers. Five healthy individuals
were discovered to carry N370S or L444P mutations. Three of these
individuals (2 heterozygous for N370S and 1 for L444P) were
anonymous blood donors, for whom future development of PD
cannot be excluded. The remaining 2 were healthy individuals
heterozygous for L444P, with no signs of PD when followed up to
ages 66 and 75 years.
The importance of these 3 variants in PD etiology in the overall
Swedish populationwas evaluated using a meta-analysis. Cochran’s
Q statistics were nonsigniﬁcant and heterogeneity was estimated
nonexistent, indicating that the results from these 2 studies are
consistent and can be compared (Table 3). Data were analyzed
under a random-effects model because we expected the effect of
these mutations to vary between southern and northern Sweden.
Pooled estimates conﬁrmed the association between L444P and
E326K and increased risk of PD, with a small effect size for E326K
(OR 1.60; 95% CI, 1.16e2.22, pc ¼ 0.026) and a large effect size for
L444P (OR 8.17; 95% CI, 2.51e26.63, pc ¼ 0.0020; Table 3). We also
found a trend for association between N370S and PD with a p-value
of 0.023, which did not remain signiﬁcant after correction for
multiple testing (OR 5.04; 95% CI, 1.10e23.04; pc ¼ 0.068).
3.2. Clinical characteristics of mutation carriers
We furthermore investigated the phenotype of patients carrying
L444P and N370S mutations (Table 4). In concert with previous
reports on PD patients with GBAmutations, we observed that many
patients had a relatively early onset (50% were aged 55 years), in
particular individuals carrying L444P mutations, who had an
average age of onset of 55.7  10.9 years, p ¼ 0.0052 as compared
with 709 of the noncarrier patients (for whom information on ageof onset was available). N370S patients had an average age of onset
of 63.6  12.2 years, which is not lower than that of the noncarrier
group (p ¼ 0.36). Apart from the age of onset, mutation carriers did
not differ signiﬁcantly from other PD patients, 24.4% had a known
familial history of PD and there were no other features indicating a
more severe or a more rapidly progressing phenotype based on the
clinical information available. Information on cognitive decline was
available for a subset of affected carriers (n ¼ 34) which allowed us
to estimate that around 20% of the mutation carriers suffer from
cognitive decline.
4. Discussion
Here, we describe a genetic study on 2 rare GBAmutations and 1
common GBA SNP in the largest Swedish PD case-control study
reported to date. We found known pathogenic GBA mutations
predominantly in PD patients. In a meta-analysis, comprising pa-
tients from the entire country, L444P strongly associated with PD,
whereas N370S showed a trend for association. The allele associa-
tion found between the minor allele of N370S and increased risk for
PD in southern Sweden further supports the importance of N370S
also in our study population. Both mutations were associated with
high ORs, and somewhat broad 95% CIs clearly separated from0.We
also found an association between E326K and PD, in agreement
with previous observations. The allele frequency for E326K in PD
described by others corresponds to our observation in the Swedish
population (Lesage et al., 2011). Because of the suggested role of
E326K as a modiﬁer (Chabas et al., 2005; Montfort et al., 2004), it
would be interesting to investigate the possible combined effect of
carrying this SNP plus one of L444P or N370S, but allele frequencies
of these 3 mutations were too low to allow for haplotype analysis.
Only 1 of the subjects in this study carried more than 1 mutated
GBA allele. This individual was heterozygous for E326K and L444P
and, with an age of onset 55 years, is not exceptional, considering
GBA mutation carriers overall have relatively early onset of symp-
toms (Gan-Or et al., 2008; Nichols et al., 2009).
The common variant E326K presented a lower OR (ORE326K ¼
1.60) than the rare mutations (ORN370S ¼ 5.04 and ORL444P ¼ 8.17),
which was also expected considering the detrimental effect of
N370S and L444P on enzyme activity. The effect of L444P was
stronger than that of N370S, which is in agreement with the clas-
siﬁcation of the L444P mutations as severe, whereas N370S is
classiﬁed as mild (Gan-Or et al., 2015; Mao et al., 2013).
The 2 mutations analyzed, L444P and N370S, were observed
more often in PD patients than in control subjects. N370Swas found
in 10 patients (0.63%), 1 of which was homozygous, and 2 were
controls (0.10%), whereas L444P was found in 35 patients (2.20%)
and 3 control individuals (0.15%). Although individuals carrying
homozygous GBA mutations usually suffer from GD, the homozy-
gous N370S mutation carrier had a clear idiopathic PD diagnosis
with no signs of dementia, when followed up at the age of 75.
Homozygous GBA mutation carriers with typical PD phenotypes
have also been reported by others (Lesage et al., 2011). The overall
occurrence of these 2 GBA variations was 2.77% in the Swedish PD
population, which is comparable with what has been reported
globally (around 3% in PD cohorts without Ashkenazi Jewish
ancestry), although this number is very different depending on
ethnicity (Sidransky et al., 2009). In Norway, the frequencies of
L444P and N370S are also somewhat lower than 3%, indicating that
these variations are not very frequent in the Scandinavian pop-
ulations (Sidransky et al., 2009; Toft et al., 2006). We observed a
clear stratiﬁcation in the Swedish population, with a higher mu-
tation load in the northern parts of the country. In total, 29 of the 50
identiﬁed GBA mutation carriers (controls and patients) were from
northern Sweden. Of these, 26 individuals were heterozygous for
Table 4
Characteristics of PD patients with GBA mutations
Genotype Origin Gender Heredity Age, y Age at onset, y Disease duration, y Hoehn and Yahr Cognitive decline
N370S þ/þ Gothenburg F N 69 66 3 NA N
N370S þ/ Gothenburg F N 66 54 12 NA NA
N370S þ/ Linköping M Y 74 68 6 NA NA
N370S þ/ Lund F N 79 70 9 5 Y
N370S þ/ Stockholm F N 56 45 11 3 NA
N370S þ/ Stockholm M N 80 78 2 4 NA
N370S þ/ Stockholm F N 86 85 1 3 NA
N370S þ/ Umeå M N 47 43 4 2 N
N370S þ/ Umeå M N 71 61 9 2 N
N370S þ/ Umeå M N 71 66 4 3 Y
L444P þ/, E326K þ/ Gothenburg M N 66 55 11 NA NA
L444P þ/ Gothenburg M N 61 61 1 NA NA
L444P þ/ Gothenburg M Y 76 67 9 NA NA
L444P þ/ Gothenburg F Y 60 52 8 NA NA
L444P þ/ Lund F N 64 57 7 3 Y
L444P þ/ Lund M Y 63 68 5 3 Y
L444P þ/ Stockholm F N 64 50 14 2 NA
L444P þ/ Stockholm M N 54 50 4 2 NA
L444P þ/ Stockholm F Y 76 75 1 NA N
L444P þ/ Stockholm M N 83 73 10 1 N
L444P þ/ Umeå M N 59 43 16 4 Y
L444P þ/ Umeå M Y 67 65 2 2 N
L444P þ/ Umeå M N 44 40 4 2 N
L444P þ/ Umeå F N 72 65 7 3 Y
L444P þ/ Umeå F N 66 63 3 3 N
L444P þ/ Umeå F N 59 48 10 3 N
L444P þ/ Umeå M Y 55 41 13 4 N
L444P þ/ Umeå M N 55 42 13 2 N
L444P þ/ Umeå M Y 48 46 2 2 N
L444P þ/ Umeå F N 52 41 10 2 N
L444P þ/ Umeå F N 58 52 5 2 N
L444P þ/ Umeå M N 62 61 1 2 N
L444P þ/ Umeå M Y 47 41 6 2 N
L444P þ/ Umeå F N 54 53 2 1.5 N
L444P þ/ Umeå F Y 75 72 3 2 N
L444P þ/ Umeå F N 58 49 8 2.5 N
L444P þ/ Umeå F N 67 57 9 2.5 N
L444P þ/ Umeå F Y 62 50 11 3 Y
L444P þ/ Umeå M N 59 61 2 2 N
L444P þ/ Umeå F N 61 62 1 2 N
L444P þ/ Umeå F N 47 43 3 2 N
L444P þ/ Umeå F Y 62 45 16 3 N
L444P þ/ Umeå M Y 65 55 10 2 N
L444P þ/ Umeå M N 83 80 2 2 N
L444P þ/ Umeå M N 71 68 2 2 N
Key: F, female; GBA, glucocerebrosidase; M, male; N, no; NA, data not available; PD, Parkinson’s disease; Y, yes.
C. Ran et al. / Neurobiology of Aging 45 (2016) 212.e5e212.e11 212.e9L444P, which corresponds to 4.11% of the PD patients in northern
Sweden, as compared with 1.02% in southern Sweden. Only 3 in-
dividuals from northern Sweden were heterozygous for N370S,
which was comparable with the percentage of heterozygous in-
dividuals in the rest of the population. These data are consistent
with the increased prevalence of Norrbottnian type GD in northern
Sweden (Norrbotten and Västerbotten), which has been linked to
homozygosity of the L444P mutation (Dahl et al., 1990).
Because our study did not include all pathogenic GBA variations
discovered, we might be overlooking important components of the
GBA contribution to PD pathology in Sweden. It is possible that
other GBA mutations, known or yet to be discovered, are more
predominant in the Swedish PD population. On the other hand, our
results suggest that GBAmutations contribute to the high incidence
of PD reported from northern Sweden, but only constitute a rare
risk factor for PD elsewhere in Sweden (Linder et al., 2010). Our
study is further limited by the uneven distribution of controls be-
tween southern and northern Sweden and by the unknown age and
speciﬁc characteristics of a large number of control subjects (n ¼
855) who were blood donors and can, therefore, be expected to
have a lower mean age at enrollment than the PD patients in this
study.In agreement with previous studies, we found that L444P mu-
tation carriers have lower age of onset of PD symptoms than non-
carriers (p ¼ 0.0052). A few controls were found to carry GBA
mutations (0.25%), 3 were anonymous blood donors and theymight
all be at risk for developing PD in the future. Finding carriers of
pathogenic mutations among controls is not unexpected, and
healthy control subjects with a copy of the N370S or L444P allele
have been reported in other populations as well (Sidransky et al.,
2009; Toft et al., 2006). Moreover, the penetrance of the L444P
mutation has been estimated to be 30% at the age of 70 (Anheim
et al., 2012). It is possible that the L444P carriers in our study
(aged 66 and 75) will develop PD with increasing age, but because
one of the hallmarks of GBA mutations is early disease onset, we
expect these individuals to remain healthy. Healthy mutation car-
riers are interesting subjects for further genetic studies, as they
might carry protective genetic variants, either generally neuro-
protective or counteracting the effect of lower GCase activity.
It is not clear how mutations in the GBA gene affect PD patho-
genesis, but there is an interesting connection to another PD
candidate gene, SNCA, which strengthens the hypothesis of
involvement of the endosomal and/or lysosome-autophagy path-
ways in PD. For example, the membrane-bound forms of
C. Ran et al. / Neurobiology of Aging 45 (2016) 212.e5e212.e11212.e10a-synuclein and GCase have been demonstrated to interact under
lysosomal conditions, leading to inhibition of GCase (Yap et al., 2011,
2013). The levels of a-synuclein protein are affected bymutations in
GBA both in cell culture and in vivo in GBA transgenic mice (Cullen
et al., 2011; Mazzulli et al., 2011). Similarly, knockdown of GBA re-
sults in increased a-synuclein levels (Mazzulli et al., 2011). It should
be noted that there are also data reporting no effect on a-synuclein
or lysosomal function of GCase inhibition (Dermentzaki et al.,
2013). However, untreated GD patients have increased plasma
levels of oligomeric a-synuclein, whereas such an increase was not
observed in GD patients having received GCase replacement ther-
apy (Pchelina et al., 2014). Inaccurate GCase handling is hypothe-
sized to result in accumulation of a-synuclein (Mazzulli et al., 2011).
The elevated a-synuclein levels observed as a result of low GCase
activity would then lead to further reduction in GCase activity and
impairment of the intracellular trafﬁcking of GCase, which becomes
retained in the endoplasmic reticulum (ER; Mazzulli et al., 2011).
Interestingly, a-synuclein accumulation can interfere with vesicle
transport between the ER and the Golgi apparatus (Cooper et al.,
2006). Furthermore, GBA mutations might impair the unfolded
protein response of the ER (Kurzawa-Akanbi et al., 2012). An
alternative explanation suggests that GBA deﬁciency impairs
autophagy and, thereby, results in a-synuclein accumulation (Du
et al., 2015). Altered expression of proteins involved in autophagy
has been observed as a result of impaired GCase activity (Du et al.,
2015; Rocha et al., 2015). Moreover, a-synuclein accumulation can
be reversed by the use of drugs inducing autophagy in cell culture
(Cullen et al., 2011; Du et al., 2015).
5. Conclusions
This genetic study has been conducted on the largest PD case-
control material yet reported from Sweden. We found N370S and
L444P predominantly in PD patients and they were signiﬁcantly
associated with PD in Sweden. Both mutations are expected to
contribute to PD pathology. How heterozygous GBA mutations
affect cellular mechanisms and contribute to PD pathogenesis is
unknown, but accumulating evidence suggest the mechanism in-
volves a-synuclein accumulation and impairment of the lysosome
and autophagy pathways. L444P mutations were more common in
northern Sweden, which is consistent with the higher incidence of
GD type III in this part of Sweden. The common variant E326K was
also found to associate with increased risk for PD in Sweden, sup-
porting a role for common genetic variations in PD etiology. Further
genetic screening and studies of GBA should bring new insights into
the pathophysiology of PD, which in turn may result in earlier
diagnosis and design of relevant therapeutic strategies.
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